Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Integra Lifesciences Holdings (IART) over the last 16 years, with Q3 2025 value amounting to $198.8 million.

  • Integra Lifesciences Holdings' Other Operating Expenses rose 783.43% to $198.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 13701.1%. This contributed to the annual value of $644000.0 for FY2022, which is 9845.93% down from last year.
  • As of Q3 2025, Integra Lifesciences Holdings' Other Operating Expenses stood at $198.8 million, which was up 783.43% from $721.4 million recorded in Q2 2025.
  • Integra Lifesciences Holdings' Other Operating Expenses' 5-year high stood at $721.4 million during Q2 2025, with a 5-year trough of -$679000.0 in Q2 2021.
  • Moreover, its 5-year median value for Other Operating Expenses was $174.7 million (2023), whereas its average is $159.5 million.
  • As far as peak fluctuations go, Integra Lifesciences Holdings' Other Operating Expenses skyrocketed by 38000.0% in 2022, and later soared by 783.43% in 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' Other Operating Expenses (Quarter) stood at -$169000.0 in 2021, then surged by 481.07% to $644000.0 in 2022, then surged by 27425.93% to $177.3 million in 2023, then rose by 11.29% to $197.3 million in 2024, then increased by 0.77% to $198.8 million in 2025.
  • Its last three reported values are $198.8 million in Q3 2025, $721.4 million for Q2 2025, and $191.9 million during Q1 2025.